Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06443723
Status:
COMPLETED
Last Update Posted:
2024-06-05
First Post:
2024-05-19
Brief Title:
Metabolic Dysfunction Associated Fatty Liver Disease in Long-Term Cholecystectomy Patients
Sponsor:
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Organization:
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Study Overview
Official Title:
Metabolic Dysfunction Associated Fatty Liver Disease in Long-Term Cholecystectomy A Cross-sectional Case-control Study
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study was to examine the association between metabolic associated fatty liver disease MAFLD in participants who had undergone cholecystectomy and those who had not undergone cholecystectomy MAFLD is defined as hepatic steatosiswith ultrasonography entity in addition to the presence of overweight or obesity diabetes mellitus or evidence of metabolic dysfunction
In this way the long-term effects of cholecystectomy surgeries which are commonly performed in the society and thought to be harmless will be evaluated
In this way the long-term effects of cholecystectomy surgeries which are commonly performed in the society and thought to be harmless will be evaluated
Detailed Description:
Cholecystectomy is known to be a harmless operation with low perioperative mortality and morbidity However the unexplained increase in metabolic disorders in cholecystectomy patients has led to the need for further investigation of cholecystectomy patients Non-alcoholic fatty liver disease is an important health problem with an average prevalence of 25 worldwide and serious hepatic and systemic complications The aim of this study was to examine the association of cholecystectomy with metabolic dysfunction associated fatty liver disease MAFLD which is an important public health problem in the long-term
This case-controlled cross-sectional study was planned to evaluate the relationship between patients who had undergone cholecystectomy with MAFLD MAFLD is defined as hepatic steatosis entity in addition to the presence of overweight or obesity diabetes mellitus or evidence of metabolic dysfunction
The study included 86 participants with cholecystectomy and 63 participants without cholecystectomy It was planned to compare the participants according to the diagnostic criteria for MAFLD with or without MAFLD
This case-controlled cross-sectional study was planned to evaluate the relationship between patients who had undergone cholecystectomy with MAFLD MAFLD is defined as hepatic steatosis entity in addition to the presence of overweight or obesity diabetes mellitus or evidence of metabolic dysfunction
The study included 86 participants with cholecystectomy and 63 participants without cholecystectomy It was planned to compare the participants according to the diagnostic criteria for MAFLD with or without MAFLD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None